Mineralys Therapeutics:靶向醛固酮,重塑心肾代谢疾病治疗格局

药研前瞻
Jan 04

摘要Mineralys Therapeutics 是一家临床阶段的生物制药公司,其全部战略核心与未来价值均寄托于一款名为Lorundrostat的口服、高选择性醛固酮合成酶抑制剂。公司致力于解决由醛固酮失调驱动的、存在巨大未满足临床需求的心肾代谢疾病,首要目标为未控制/难治性高血压。最新资料显示,其关键性临床试验数据积极,并计划于2025年末至2026年初提交新药申请。凭借清晰的作用机制、显著的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10